OpGen (OPGN) to Release Quarterly Earnings on Thursday

OpGen (NASDAQ:OPGN – Get Rating) is scheduled to announce its earnings results after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

OpGen (NASDAQ:OPGN – Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.05 million. OpGen had a negative net margin of 680.36% and a negative return on equity of 72.67%. On average, analysts expect OpGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OpGen Trading Up 6.4 %

Shares of OpGen stock opened at $0.59 on Thursday. The company’s fifty day simple moving average is $0.55 and its 200-day simple moving average is $0.66. The company has a market cap of $27.24 million, a price-to-earnings ratio of -0.69 and a beta of -0.37. The company has a current ratio of 1.76, a quick ratio of 1.69 and a debt-to-equity ratio of 0.23. OpGen has a 1 year low of $0.31 and a 1 year high of $3.72.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on OPGN shares. StockNews.com started coverage on shares of OpGen in a research note on Thursday, July 28th. They issued a “sell” rating on the stock. Alliance Global Partners downgraded shares of OpGen to a “neutral” rating in a research note on Tuesday, July 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OpGen in a research note on Friday, June 10th.

OpGen Company Profile

(Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

• Get a free copy of the StockNews.com research report on OpGen (OPGN)
• There Are Different Types of Stock To Invest In
• Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
• PayPal Continues To Struggle As Competition Increases
• Two High-Yield Deep-Values You Shouldn’t Ignore 
• Is Starbucks Shooting For The Moon? 

Want More Great Investing Ideas?